Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 42.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (16.4%)
  • Dividend yield for the last twelve months 2.2%
  • Free cash flow yield -1.5% (LTM)
  • Share price is 68.9% higher than minimum and 0.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (16.9x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+0.9%)239.99
year average price 176.95  


year start price 153.01 2025-02-08

min close price 146.36 2025-05-14

max close price 239.99 2026-02-06

current price 239.99 2026-02-07
Common stocks: 2 631 399 832

Dividend Yield:  2.2%
FCF Yield LTM: -1.5%
EV / LTM EBITDA: 16.9x
EV / EBITDA annualized: 17.8x
Last revenue growth (y/y):  +6.8%
Last growth of EBITDA (y/y):  +78.8%
Historical revenue growth:  +2.3%
Historical growth of EBITDA:  +30.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 631 510
Net Debt ($m): 27 233
EV (Enterprise Value): 658 743
EBITDA LTM ($m): 38 890
EV / LTM EBITDA: 16.9x
Price to Book: 8.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-06businesswire.com

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

2026-02-03forbes.com

What's Behind The 50% Surge In JNJ Stock?

2026-02-03globenewswire.com

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

2026-02-01defenseworld.net

Winnow Wealth LLC Has $1.71 Million Position in Johnson & Johnson $JNJ

2026-01-30fool.com

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?

2026-01-30seekingalpha.com

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

2026-01-29reuters.com

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

2026-01-28zacks.com

Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?

2026-01-28seekingalpha.com

Johnson & Johnson: Strong Momentum Heading Into 2026

2026-01-27prnewswire.com

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data